Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial
Articolo
Data di Pubblicazione:
2016
Citazione:
Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial / Demissei, Biniyam G; Postmus, Douwe; Liu, Licette C Y; Cleland, John G; O'Connor, Christopher M; Metra, Marco; Ponikowski, Piotr; Teerlink, John R; Cotter, Gad; Davison, Beth A; Edwards, Christopher; Givertz, Michael M; Bloomfield, Daniel M; Dittrich, Howard C; Voors, Adriaan A; Hillege, Hans L. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 1874-1754. - 223:(2016), pp. 967-975. [10.1016/j.ijcard.2016.08.271]
Abstract:
The selective adenosine A1 receptor antagonist rolofylline showed a neutral overall result on clinical outcomes in the PROTECT trial. However, we hypothesized that response to rolofylline treatment could be influenced by underlying clinical risk.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acute heart failure; Heterogeneity of treatment effect; Multivariable risk; Rolofylline; STEPP; Subgroup analysis
Elenco autori:
Demissei, Biniyam G; Postmus, Douwe; Liu, Licette C Y; Cleland, John G; O'Connor, Christopher M; Metra, Marco; Ponikowski, Piotr; Teerlink, John R; Cotter, Gad; Davison, Beth A; Edwards, Christopher; Givertz, Michael M; Bloomfield, Daniel M; Dittrich, Howard C; Voors, Adriaan A; Hillege, Hans L
Link alla scheda completa:
Pubblicato in: